NGN Capital led a $15 million Series B financing of Cerapedics,
Inc., a medical device company that is developing a bone
graft substitute for use in spinal fusion surgery and other
Cerapedics’ i-Factor putty, a novel osteobiologic
that includes a small peptide, enhances the natural bone
healing process but at a much lower cost than the leading
bone growth factor. Compared with the other options currently
in use, it is a more reliable enhancer of fusion and/or
has fewer potential side effects. i-Factor is currently
being evaluated in a large U.S. clinical trial that is expected
to prove that it is both safe and highly effective. i-Factor
carries the CE mark and is currently being sold outside
Noah J. Kroloff holds a seat on the board of directors
and Kenneth S. Abramowitz holds an observer seat.
Cerapedics is located in Westminster, CO.
NGN Capital led a CHF 37.4M Series C financing of Endosense SA, a commercial stage medical device company focused on minimally invasive treatment of cardiac arrhythmias.
Endosense has developed a unique and proprietary catheter ablation system for the treatment of atrial fibrillation. The company pioneered the use of contact-force measurement in catheter ablation with the development of TactiCath, the first force sensing ablation catheter to give physicians a real-time, quantitative and objective measure of contact force between the catheter tip and the beating heart wall during the ablation procedure. The product is CE marked and being distributed in Europe and other countries.
In August of 2003, Endosense was acquired by St. Jude Medical.
Endosense is headquartered in Meryn/Geneva, Switzerland.
NGN Capital and Forbion Capital Partners co-led a $20 million Series A financing of Exosome Diagnostics, a developer of proprietary body-fluid based molecular diagnostic tests with applications in oncology.
Exosome Diagnostics is developing body fluid-based cancer diagnostics using its exosome-based technology for disease stratification and patient response monitoring. Exosome Diagnostics' technology allows for minimally invasive testing of cancer specific genes from standard blood and urine samples.
Dr. Peter Johann holds a seat on the board of directors.
Exosome Diagnostics is headquartered in Boston, MA, and has a subsidiary in Munich, Germany.
Capital led a $10.5 million Series C financing of Medrium,
Inc., a roll-up of medical billing practices.
Medrium offers outsourced billing services for high-volume,
hospital-based physician practices primarily in the emergency
medicine and radiology specialties. With dedicated resources
and proprietary technology, Medrium provides several benefits
to clients such as reduced error/rejection rates, faster
reimbursement from payers, improved operational workflow,
and sophisticated analytics for managing time per procedure.
Medrium’s growth strategy involves completing acquisitions
in key specialties or geographic regions in a manner that
would take advantage of its existing technology and expertise.
In October 2012, Medrium was acquired by AdvantEdge Healthcare Solutions.
Medrium is headquartered in Morristown, NJ.
Pharma AG (NOXXON)
Capital led a €33 million Series D round of financing,
joined by existing investors TVM Capital, Sofinnova Partners,
Edmond de Rothschild Investment Partners, Seventure Partners,
NOXXON Pharma AG (NOXXON) is a clinical stage biotechnology
company focused on the development of mirror image oligonucleotide
therapeutics called Spiegelmers® for the treatment of
inflammatory diseases and hematological disorders. Currently,
the company has two compounds in clinical development, and
one entering clinical development in 2011. The company has
pre-clinical Spiegelmers in additional indications
Dr. Peter Johann holds a seat on the board of directors.
Noxxon AG is based in Berlin , Germany
NGN Capital led a $20 million PIPE financing of Resverlogix
Corp., a publicly traded biotechnology company listed on
the Toronto Stock Exchange (TSX).
Resverlogix is a clinical stage company with a proprietary
platform for discovery and development of orally available
small molecule inducers of ApoA1, a key functional component
of HDL (the “good” cholesterol). Resverlogix
also has programs to develop compounds that target molecular
markers of inflammation for the treatment of cardiovascular
disorders and Alzheimer´s Disease.
Dr. Peter Johann holds a seat on Resverlogix’ board
Resverlogix is located in Calgary, Alberta.
NGN Capital participated in a $20 million Series D financing of Spine View, Inc., a medical device company that has developed and is selling unique less invasive powered tools for use in spine surgery and treatment.
SpineView’s powered tools remove tissue more quickly, more completely and with less risk than the current standard method, which is highly invasive scraping using simple manual tools. In the case of surgical discectomy, the company’s drill-like tools enable faster and easier fusion procedures as a result of more complete and efficient tissue removal. In the case of non-surgical, or interventional, procedures, the company’s spinning needle-like devices allow for rapid tissue removal with a minimal incision and are used in spine fusion and disc decompression.
Kenneth S. Abramowitz holds an observer seat on the board of directors.
SpineView is located in Fremont, CA.
Capital led a $7.75 million Series B financing of Valtech
Cardio, Ltd., a medical device company engaged in mitral
valve repair using minimally invasive technology.
Currently, repair of the mitral valve requires open heart
surgery. Valtech’s technology will allow for repair
of the mitral valve via a minimally invasive procedure.
Conversion of mitral valve repair to less invasive methods
is expected to reduce the risk, duration and cost of such
procedures and also considerably increase the pool of candidate
patients, many of whom are otherwise clinically unsuitable
for a traumatic open heart procedure.
Kenneth S. Abramowitz and Noah J. Kroloff hold seats on the board of directors and John R. Costantino holds an observer seat.
Valtech Cardio, Ltd. is located in Or-Yehuda, Israel.
Capital co-led an initial investment of a targeted $30 million
Series A financing of Vivaldi Biosciences, Inc.
Vivaldi is an emerging flu vaccine company developing unique
live attenuated vaccines for seasonal and pandemic influenza.
Dr. Peter Johann and John Costantino hold seats on the
board of directors.
Vivaldi is based in New York, New York.